A blood-based test has acceptable accuracy for colorectal cancer detection but not for advanced precancerous lesions in an ...

Let’s make June a turning point where more people get screened, more cancers are caught early and fewer lives are lost.

New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial ...

Guardant Health's Shield multi-cancer detection (MCD) test has secured the US Food and Drug Administration’s (FDA) ...

A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.

Freenome plans to complete all modules of its premarket approval submission in mid-2025.